during the fiscal year. A copy of the report will be provided to the Department’s Committee Management Officer.

Nominations. Nominations, including self-nominations, of individuals who have the specified expertise and knowledge will be considered for appointment as members of the Commission. A nomination should include, at a minimum, the following for each nominee: (1) A letter of nomination that clearly states the name and affiliation of the nominee, the basis for the nomination, and a statement from the nominee that indicates that the individual is willing to serve as a member of the Commission, if selected; (2) a one-page biography that describes the nominee’s qualifications and, if applicable, highlights relevant experience on other federal advisory committees; (3) the nominator’s name, address, and daytime telephone number; and the address, telephone number, and email address of the individual being nominated; and (4) a current copy of the nominee’s curriculum vitae or resume, which should be limited to no more than 30 pages. Incomplete nomination packages will not be reviewed.

Every effort will be made to ensure that the composition of the Commission includes individuals from various geographic locations, including rural and underserved areas; racial and ethnic minorities; genders, and persons living with disabilities. Individuals other than officers or employees of the United States government being considered for appointment as members of the Commission will be required to complete and submit a report of their financial holdings. An ethics review must be conducted to ensure that individuals appointed as members of the Commission are not involved in any activity that may pose a potential conflict of interest for the official duties that are to be performed. This is a federal ethics requirement that must be satisfied upon entering the position and annually throughout the established term of appointment on the Commission.

has been finalized. All agenda items are tentative and subject to change.

Public attendance at the meeting is limited to the available space. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Advisory Council at the address/telephone number listed above at least one week prior to the meeting. For those unable to attend in person, a live webcast will be available. More information on registration and accessing the webcast can be found at http://www.hhs.gov/ash/carb/.

Members of the public will have the opportunity to provide comments prior to the Advisory Council meeting by emailing CARB@hhs.gov. Public comments should be sent in by midnight May 9, 2018, and should be limited to no more than one page. All public comments received prior to May 9, 2018, will be provided to Advisory Council members; comments are limited to two minutes per speaker.

Dated: April 19, 2018.

Jomana F. Musmar,
Acting Designated Federal Officer, Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria Committee Manager.

[FR Doc. 2018–08883 Filed 4–25–18; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Meeting of the Tick-Borne Disease Working Group

AGENCY: Office of HIV/AIDS and Infectious Disease Policy, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services (HHS) announces the fifth in-person meeting of the Tick-Borne Disease Working Group (Working Group) on May 15–16, 2018, from 9:00 a.m. to 7:45 p.m. Eastern Time on May 15 and from 9:00 a.m. to 5:30 p.m. Eastern Time on May 16. For this fifth meeting, the Working Group will provide an overview of the report to the HHS Secretary and Congress and discuss what should be included in the report from the work of the six Subcommittee Working Groups that were established on December 12, 2017. These subcommittees were established to assist the Working Group with the development of the report to Congress and the HHS Secretary as required by the 21st Century Cures Act. The subcommittees are:

1. Disease Vectors, Surveillance and Prevention (includes epidemiology of tick-borne diseases);
2. Pathogenesis, Transmission, and Treatment;
3. Testing and Diagnostics (including laboratory-based diagnoses and clinical-diagnoses);
4. Access to Care Services and Support to Patients;
5. Vaccines and Therapeutics; and
6. Other Tick-Borne Diseases and Co-infections.

DATES: May 15, 2018, from 9:00 a.m. to 7:45 p.m. Eastern Time and May 16, 2018, from 9:00 a.m. to 5:30 p.m. Eastern Time.


Members of the public may also attend the meeting via webcast. Instructions for attending the meeting via webcast will be posted one week prior to the meeting at: https://www.hhs.gov/ash/advisory-committees/tickborne disease/index.html.

FOR FURTHER INFORMATION CONTACT: James Berger, Office of HIV/AIDS and Infectious Disease Policy, Office of the Assistant Secretary for Health, Department of Health and Human Services; via email at tickborne disease@hhs.gov or by phone at 202–795–7697.

SUPPLEMENTARY INFORMATION:

In-person attendance at the meeting is limited to space available; therefore, preregistration for public members is advisable and can be accomplished by registering at http://events.r20.constantcontact.com/register/event?llr=zz7zpztzab&oeidk=a07edrodofu088eae0cf by Thursday, May 10, 2018. On the day of the meeting, seating will be provided first to persons who have preregistered. People who have not preregistered will be accommodated on a first come, first served basis if additional seats are still available 10 minutes before the meeting start. Non-U.S. citizens who plan to attend in person are required to provide additional information and must notify the Working Group support staff via email at tickborne disease@hhs.gov before April 30, 2018.

The Working Group invites public comment on issues related to the Working Group’s charge. It may be provided in-person at the meeting or in writing. In-person comments will occur from 9:05 a.m. to 10:05 a.m. on May 16, 2018. Persons who wish to provide public comment in person should review directions at https://www.hhs.gov/ash/advisory-committees/tickborne disease/meetings/index.html before submitting a request to do so via email at tickborne disease@hhs.gov.

Requests to provide in-person comment are due on or before May 10, 2018. In-person comments will be limited to three minutes each to accommodate as many speakers as possible. If more requests are received than can be accommodated, speakers will be randomly selected. The nature of the comments will not be considered in making this selection. Public comments may also be provided in writing.

Individuals who would like to provide written comment should review directions at https://www.hhs.gov/ash/advisory-committees/tickborne disease/meetings/index.html before sending their comments to tickborne disease@hhs.gov on or before May 10, 2018.

Background and Authority: The Tick-Borne Disease Working Group was established on August 10, 2017, in accordance with section 2062 of the 21st Century Cures Act, and the Federal Advisory Committee Act, 5 U.S.C. App., as amended, to provide expertise and review all HHS efforts related to tick-borne diseases to help ensure interagency coordination and minimize overlap, examine research priorities, and identify and address unmet needs. In addition, the Working Group will report to the Secretary and Congress on their findings and any recommendations for the federal response to tick-borne disease prevention, treatment and research, and addressing gaps in those areas.

Dated: April 19, 2018.

James Berger,
Alternate Designated Federal Officer, Office of HIV/AIDS and Infectious Disease Policy, Tick-Borne Disease Working Group.

[FR Doc. 2018–08786 Filed 4–25–18; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material,